Getagraph.com logo
NASDAQ Composite: ( -0.01%) 16 735
S&P 500
(0.80%) 5 277.51 points
Dow Jones
(1.51%) 38 686 points
Nasdaq
(-0.01%) 16 735 points
Oil
(-0.94%) $77.18
Gas
(0.35%) $2.58
Gold
(-0.79%) $2 347.70
Silver
(-3.10%) $30.56
Platinum
(0.63%) $1 044.50
USD/EUR
(-0.17%) $0.921
USD/NOK
(-0.49%) $10.49
USD/GBP
(-0.05%) $0.785
USD/RUB
(0.15%) $90.40

Realtime updates for Passage Bio Inc [PASG]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Last Updated31 May 2024 @ 16:00
25% discount on Stockinvest.us - Use code: Podcast

-0.87% $ 1.140

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease...

Stats
Today's Volume 68 707.00
Average Volume 293 447
Market Cap 70.27M
EPS $0 ( 2024-05-21 )
Next earnings date ( $-0.310 ) 2024-08-05
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.750
ATR14 $0.0170 (1.55%)
Insider Trading
Date Person Action Amount type
2024-05-21 Countouriotis Athena Buy 47 693 Director Stock Option (right to buy)
2024-05-21 Gowen Maxine Buy 47 693 Director Stock Option (right to buy)
2024-05-21 Kapadia Sandip Buy 47 693 Director Stock Option (right to buy)
2024-05-21 Islam Saqib Buy 47 693 Director Stock Option (right to buy)
2024-05-21 Sondhi Dolan Buy 39 092 Director Stock Option (right to buy)
INSIDER POWER
82.95
Last 97 transactions
Buy: 8 193 316 | Sell: 441 732

Volume Correlation

Long: -0.06 (neutral)
Short: -0.53 (weak negative)
Signal:(44.49) Neutral

Passage Bio Inc Correlation

10 Most Positive Correlations
REYN0.88
POWL0.873
VEON0.861
CLBT0.86
CFLT0.854
MRUS0.851
FWRG0.846
EQ0.842
MEDP0.837
MACK0.835
10 Most Negative Correlations
CYAN-0.857
CAR-0.831
WTER-0.829
SSRM-0.829
FINW-0.827
BIOL-0.826
EGAN-0.821
KRKR-0.818
VREX-0.813
BLKB-0.809

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Passage Bio Inc Correlation - Currency/Commodity

The country flag -0.38
( neutral )
The country flag 0.28
( neutral )
The country flag 0.00
( neutral )
The country flag -0.13
( neutral )
The country flag 0.63
( weak )
The country flag -0.71
( moderate negative )

Passage Bio Inc Financials

Annual 2023
Revenue: $0
Gross Profit: $-3.72M (0.00 %)
EPS: $-1.860
FY 2023
Revenue: $0
Gross Profit: $-3.72M (0.00 %)
EPS: $-1.860
FY 2022
Revenue: $0
Gross Profit: $-3.68M (0.00 %)
EPS: $-2.51
FY 2021
Revenue: $0.00
Gross Profit: $0.00 (0.00 %)
EPS: $-3.48

Financial Reports:

No articles found.

Passage Bio Inc Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Passage Bio Inc

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Total Execution Time: 1.0498170852661 seconds
Number of API calls: 2
Number of DB calls: 8